LETROZOLE DEXCEL

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

LETROZOLE

Disponible depuis:

DEXCEL LTD, ISRAEL

Code ATC:

L02BG04

forme pharmaceutique:

FILM COATED TABLETS

Composition:

LETROZOLE 2.5 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

HAUPT PHARMA MUNSTER GmbH, GERMANY

Groupe thérapeutique:

LETROZOLE

Domaine thérapeutique:

LETROZOLE

indications thérapeutiques:

Letrozole - Dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole - Dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Date de l'autorisation:

2016-02-29